Recently, three companies from the mother fund portfolio managed by Yuanhe Chencun successfully passed the review on the STAR Market: Shanghai Junshi Biosciences Co., Ltd. (hereafter referred to as "Junshi Biosciences"), Beijing Shenzhou Cell Biotechnology Group Co., Ltd. (hereafter referred to as "Shenzhou Cell"), and Beijing Tianzhihang Medical Technology Co., Ltd. (hereafter referred to as "Tianzhihang").

Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery and development of groundbreaking drugs, as well as global clinical research and commercialization efforts. The company was listed on the Hong Kong stock market in 2018 and later successfully achieved a dual listing of H-shares and A-shares following its IPO on the STAR Market.

Shenzhou Cell focuses on the research, development, and industrialization of biopharmaceutical products across multiple therapeutic and preventive areas, including malignant tumors, autoimmune diseases, infectious illnesses, and genetic disorders. It is an innovative biopharmaceutical company dedicated to developing cutting-edge biologics that offer distinctive competitive advantages.

Tianzhihang is the first domestic and fifth global medical device company to obtain a registration license for surgical robots, primarily focusing on the research, development, manufacturing, and sales of orthopedic surgery navigation and positioning robots.